Swiss National Bank Alaunos Therapeutics, Inc. Transaction History

Swiss National Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.41 - $1.24 $209,559 - $633,788	-511,120 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$0.62 - $1.17 $24,056 - $45,396	38,800 Added 8.21%	511,120 $333,000
Q2 2021 Aug 06, 2021	SELL	$2.63 - $3.67 $45,499 - $63,491	-17,300 Reduced 3.53%	472,320 $1.25 Million
Q1 2021 May 07, 2021	BUY	$2.82 - $5.6 $11,280 - $22,400	4,000 Added 0.82%	489,620 $1.76 Million
Q3 2020 Nov 09, 2020	BUY	$2.39 - $3.43 $46,366 - $66,542	19,400 Added 4.16%	485,620 $1.22 Million
Q2 2020 Aug 05, 2020	BUY	$2.2 - $3.71 $134,640 - $227,052	61,200 Added 15.11%	466,220 $1.53 Million
Q1 2020 May 08, 2020	BUY	$1.9 - $4.98 $266,950 - $699,690	140,500 Added 53.12%	405,020 $992,000
Q4 2019 Feb 06, 2020	BUY	$3.95 - $5.35 $22,120 - $29,959	5,600 Added 2.16%	264,520 $1.25 Million
Q3 2019 Nov 12, 2019	BUY	$4.13 - $6.94 $16,933 - $28,454	4,100 Added 1.61%	258,920 $1.11 Million
Q2 2019 Aug 02, 2019	BUY	$3.98 - $6.2 $105,868 - $164,920	26,600 Added 11.66%	254,820 $1.49 Million
Q4 2018 Feb 13, 2019	BUY	$1.61 - $3.62 $14,973 - $33,666	9,300 Added 4.25%	228,220 $427,000
Q3 2017 Nov 03, 2017	BUY	$4.99 - $6.57 $1.09 Million - $1.44 Million	218,920	218,920 $1.34 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.